Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study

M. Schuler; U. Bruntsch; E. Späth-Schwalbe; H. Schrezenmeier; C. Peschel; L. Färber; K. J. Burger; J. Leiner; C. Huber; W. E. Aulitzky

doi:10.1016/S0959-8049(97)10089-2

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study

M. Schuler, U. Bruntsch, E. Späth-Schwalbe, H. Schrezenmeier, C. Peschel, L. Färber, K. J. Burger, J. Leiner, C. Huber, W. E. Aulitzky

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

The present phase H study was undertaken to assess antitumoral activity, safety and tolerabillty of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 μg/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute phase response were observed in most patients. In conclusion, prolonged subcutaneous administration of rh IL-6 on an outpatient basis is safe and feasible. However, rh IL-6 exhibited no antitumoral activity in patients with metastastic renal cell cancer. Profound regulatory effects on haematopoiesis and inflammatory response of rh IL-6 were observed.

Original language	English
Pages (from-to)	754-756
Number of pages	3
Journal	European Journal of Cancer
Volume	34
Issue number	5
DOIs	https://doi.org/10.1016/S0959-8049(97)10089-2
State	Published - Apr 1998
Externally published	Yes

Keywords

Cancer
Immunotherapy
Interleukin-6
Kidney neoplasms
Therapeutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(97)10089-2

Cite this

Schuler, M., Bruntsch, U., Späth-Schwalbe, E., Schrezenmeier, H., Peschel, C., Färber, L., Burger, K. J., Leiner, J., Huber, C., & Aulitzky, W. E. (1998). Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study. European Journal of Cancer, 34(5), 754-756. https://doi.org/10.1016/S0959-8049(97)10089-2

@article{29ec9bb44d4c44e6b38a50f33d4cf57a,

title = "Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study",

abstract = "The present phase H study was undertaken to assess antitumoral activity, safety and tolerabillty of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 μg/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute phase response were observed in most patients. In conclusion, prolonged subcutaneous administration of rh IL-6 on an outpatient basis is safe and feasible. However, rh IL-6 exhibited no antitumoral activity in patients with metastastic renal cell cancer. Profound regulatory effects on haematopoiesis and inflammatory response of rh IL-6 were observed.",

keywords = "Cancer, Immunotherapy, Interleukin-6, Kidney neoplasms, Therapeutics",

author = "M. Schuler and U. Bruntsch and E. Sp{\"a}th-Schwalbe and H. Schrezenmeier and C. Peschel and L. F{\"a}rber and Burger, {K. J.} and J. Leiner and C. Huber and Aulitzky, {W. E.}",

year = "1998",

month = apr,

doi = "10.1016/S0959-8049(97)10089-2",

language = "English",

volume = "34",

pages = "754--756",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "5",

}

Schuler, M, Bruntsch, U, Späth-Schwalbe, E, Schrezenmeier, H, Peschel, C, Färber, L, Burger, KJ, Leiner, J, Huber, C & Aulitzky, WE 1998, 'Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study', European Journal of Cancer, vol. 34, no. 5, pp. 754-756. https://doi.org/10.1016/S0959-8049(97)10089-2

TY - JOUR

T1 - Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer

T2 - Results of a phase II study

AU - Schuler, M.

AU - Bruntsch, U.

AU - Späth-Schwalbe, E.

AU - Schrezenmeier, H.

AU - Peschel, C.

AU - Färber, L.

AU - Burger, K. J.

AU - Leiner, J.

AU - Huber, C.

AU - Aulitzky, W. E.

PY - 1998/4

Y1 - 1998/4

N2 - The present phase H study was undertaken to assess antitumoral activity, safety and tolerabillty of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 μg/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute phase response were observed in most patients. In conclusion, prolonged subcutaneous administration of rh IL-6 on an outpatient basis is safe and feasible. However, rh IL-6 exhibited no antitumoral activity in patients with metastastic renal cell cancer. Profound regulatory effects on haematopoiesis and inflammatory response of rh IL-6 were observed.

AB - The present phase H study was undertaken to assess antitumoral activity, safety and tolerabillty of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 μg/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute phase response were observed in most patients. In conclusion, prolonged subcutaneous administration of rh IL-6 on an outpatient basis is safe and feasible. However, rh IL-6 exhibited no antitumoral activity in patients with metastastic renal cell cancer. Profound regulatory effects on haematopoiesis and inflammatory response of rh IL-6 were observed.

KW - Cancer

KW - Immunotherapy

KW - Interleukin-6

KW - Kidney neoplasms

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=0032055560&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)10089-2

DO - 10.1016/S0959-8049(97)10089-2

M3 - Article

C2 - 9713286

AN - SCOPUS:0032055560

SN - 0959-8049

VL - 34

SP - 754

EP - 756

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 5

ER -

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this